Background: The male breast cancer (MBC) is a rare disease and represents less than 1% of all malignancies in men and less than 1% of all breast cancers incident. Aim of study: In this descriptive retrospective study we aimed to provide clinico-epidemiological characteristics of MBC. To present the treatment given with respect to DFS , TTP & OS, to identify possible prognostic factors of the disease and the toxicities encountered by the treatment given. Patients and Method: Out of 11313 cancer patients 3046 were breast cancer; 28 of them were MBC. All patients presented to clinical oncology department in Ain Shams University in the period from January 2008 to December 2014 and follow up till December 2016 Results: The median age of patients was 59 years. Around 90% had hormone receptor positive (estrogen and/or progesterone receptors).Two third of the patients had advanced T-stage (T3 and T4). Infiltrating ductal carcinoma the most common type of histology was encountered. Modified radical mastectomy was the most common (75%) type of surgery done followed by chemotherapy for 21 patients and loco-regional radiotherapy for 20 patients. Tamoxifen was administered in 19 patients. Relapse occurred in 14 patients (50%). The 5-year disease-free survival (DFS) was 21.4%, the 5-year time to progression (TTP) rate was 21.4% and the 5-year old overall survival (OS) rate was 35.7%. Conclusion: There is always a delay in the male patients since the first complaint until they seek medical advice, which results in an advanced disease at presentation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.